BLAINJECTIONINJECTABLE
Approved
Sep 2021
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
BYOOVIZ (ranibizumab-nuna) by Samsung Bioepis is vascular endothelial growth factor inhibitors [moa]. First approved in 2021.
Drug data last refreshed Yesterday
Mechanism of Action
Vascular Endothelial Growth Factor Inhibitors
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on BYOOVIZ at Samsung Bioepis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.